Monitoring the developing Multiple Myeloma (MM) chessboard CELG first articulated in May2018 | BMY Message Board Posts


Bristol-Myers Squibb Co.

  BMY website

BMY   /  Message Board  /  Read Message

 

 






Keyword
Subject
Between
and
Rec'd By
Authored By
Minimum Recs
  
Previous Message  Next Message    Post Message    Post a Reply return to message boardtop of board
Msg  10146 of 10341  at  8/15/2022 7:51:52 AM  by

grafzeppelin


 In response to msg 10145 by  Biotech2050
view thread
Strong Buy

Re: Monitoring the developing Multiple Myeloma (MM) chessboard CELG first articulated in May2018

 might happen anyway if this remains true per usual JBWIN tour de force post:
 
"IBER's safety profile is quite differentiated with almost no non-hematological Grade 3 or higher serious adverse events (SAE) lending itself to broad combinations in early lines." 


     e-mail to a friend      printer-friendly     add to library      
|  
Recs: 10  
   Views: 0 []
Previous Message  Next Message    Post Message    Post a Reply return to message boardtop of board




Financial Market Data provided by
.
Loading...